# Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

> **NCT01700673** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 25 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Azacitidine
- **BIOLOGICAL:** Sargramostim

## Key facts

- **NCT ID:** NCT01700673
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2020-06
- **Final completion:** 2020-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01700673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01700673, "Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01700673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*